




PHARMACEUTICAL 2021

Viracta Therapeutics Inc.
Rank 207 of 402





RealRate

PHARMACEUTICAL 2021

Viracta Therapeutics Inc.
Rank 207 of 402



The relative strengths and weaknesses of Viracta Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viracta Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 47% points. The greatest weakness of Viracta Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 84% points.

The company's Economic Capital Ratio, given in the ranking table, is 96%, being 48% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	22,144
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,310
Liabilities, Non-Current	0
Other Assets	1,103
Other Compr. Net Income	-1.0
Other Expenses	302
Other Liabilities	0
Other Net Income	995
Other Revenues	120
Property and Equipment	0
Research and Development	12,259
Selling, General and Administrative Expense	10,164

Output Variable	Value in 1000 USD
Assets	23,247
Liabilities	3,310
Expenses	22,725
Revenues	120
Stockholders Equity	19,937
Net Income	-21,610
Comprehensive Net Income	-21,610
Economic Capital Ratio	96%